The subject of the patent application are compounds that inhibit transcription factors from the Grainyhead-like (GRHL) family, especially GRHL2, as well as the use of these compounds in the treatment of diseases dependent on the functioning of this protein, in particular in the treatment of cancer.

Nencki Institute is the co-applicant with University of Warsaw and National Medicines Institutes. University of Warsaw is the leader in patent protection and commercialization-related activities.

For more information contact Technology Transfer Office.